Concepedia

Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase

Monika Malm-Erjefält, Inga Bjørnsdottir, Jan Vanggaard, Hans Helleberg, Uffe S. Larsen, B. Oosterhuis, Jan Jaap van Lier, Milan Zdravkovic

Drug Metabolism and Disposition · 2010 · 197 citations · 28 references

DOI

Concepts

References

28

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

Rolf Mentlein, Baptist Gallwitz, Wolfgang E. Schmidt · European Journal of Biochemistry · 1993 · 1.2K citations · Full text

, , +17

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

Michael A. Nauck, Anders Frid, Kjeld Hermansen et al. · Diabetes Care · 2008 · 1.1K citations · Full text

, , +17

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

Alan J. Garber, Robert R. Henry, Robert E. Ratner et al. · The Lancet · 2008 · 1.1K citations

, , +13

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Carolyn F. Deacon, Anders H. Johnsen, Jens J. Holst · The Journal of Clinical Endocrinology & Metabolism · 1995 · 757 citations

, , +16

Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects

Carolyn F. Deacon, Michael A. Nauck, M. Toft-Nielsen et al. · Diabetes · 1995 · 716 citations

, , +7